AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
🇿🇼
IMATINIB MESYLATE in Zimbabwe
7 products registered with MCAZ — 7 active
| Brand / Product | Reg. No. | Holder | Status | Expires |
|---|---|---|---|---|
| TYKONIB 400 TABLET, COATED; ORAL | 2021/9.4/6201 | MSN LABORATORIES PRIVATE LIMITED | active | 8 Aug 2029 |
| TYKONIB 100 TABLET, COATED; ORAL | 2021/9.4/6202 | MSN LABORATORIES PRIVATE LIMITED | active | 8 Aug 2029 |
| IMAREM TABLET, COATED; ORAL | 2023/9.4/6409 | REMEDICA LTD | active | 17 May 2028 |
| IMAREM TABLET, COATED; ORAL | 2023/9.4/6408 | REMEDICA LTD | active | 17 May 2028 |
| IMATIB CAPSULE; ORAL | 2021/9.4/6096 | CIPLA LTD | active | 31 Dec 2027 |
| MATIS TABLET; ORAL | 2017/9.4/5347 | KEY ONCOLOGICS (PYT) LTD | active | 31 Dec 2027 |
| IMATIB CAPSULE; ORAL | 2021/9.4/6097 | CIPLA LTD | active | 31 Dec 2027 |
IMATINIB MESYLATE — MCAZ Registration Details
MCAZ (Zimbabwe) has 7 registered products containing IMATINIB MESYLATE, of which 7 are currently active. Data is sourced directly from the official MCAZ drug register and refreshed daily.
Track IMATINIB MESYLATE registration expiry dates, monitor competitor approvals, and receive alerts when registration status changes. Create a free account to set up portfolio monitoring.